What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review

• Published in: International journal of nanomedicine Vol. 19; pp. 9503 - 9547
• Main Authors: Szupryczyński, Kamil, Czeleń, Przemysław, Jeliński, Tomasz, Szefler, Beata
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.09.2024; Dove; Dove Medical Press
• Subjects: Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cancer; cancer treatment; carboplatin; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemotherapy; Cisplatin; drug delivery; Drug delivery systems; Drug Interactions; Drug therapy; Drugs; fullerenes; heptaplatin; Humans; lobaplatin; Lung cancer; Lung Neoplasms - drug therapy; Nanomedicine; nanoparticles; Nanostructures - chemistry; Nanostructures - therapeutic use; nanotube; nedaplatin; niacin (b3); Nitrogen; oxaliplatin; personalized medicine; platinum-based drugs; pyridoxal phosphate (b6); Radiotherapy; Respiratory agents; Review; riboflavin (b2); Small Cell Lung Carcinoma - drug therapy; thiamine (b1); Vehicles; vitamin b; Poland; nanoparticles; platinum-based drugs; carboplatin; nedaplatin; oxaliplatin; fullerenes; drug delivery; cisplatin; nanotube; personalized medicine
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S469217

Over the course of several decades, anticancer treatment with chemotherapy drugs for lung cancer has not changed significantly. Unfortunately, this treatment prolongs the patient's life only by a few months, causing many side effects in the human body. It has also been proven that drugs such as Cisplatin, Carboplatin, Oxaliplatin and others can react with other substances containing an aromatic ring in which the nitrogen atom has a free electron group in its structure. Thus, such structures may have a competitive effect on the nucleobases of DNA. Therefore, scientists are looking not only for new drugs, but also for new alternative ways of delivering the drug to the cancer site. Nanotechnology seems to be a great hope in this matter. Creating a new nanomedicine would reduce the dose of the drug to an absolute minimum, and thus limit the toxic effect of the drug; it would allow for the exclusion of interactions with competitive compounds with a structure similar to nucleobases; it would also permit using the so-called targeted treatment and bypassing healthy cells; it would allow for the introduction of other treatment options, such as radiotherapy directly to the cancer site; and it would provide diagnostic possibilities. This article is a review that aims to systematize the knowledge regarding the anticancer treatment of lung cancer, but not only. It shows the clear possibility of interactions of chemotherapeutics with compounds competitive to the nitrogenous bases of DNA. It also shows the possibilities of using nanostructures as potential Platinum drug carriers, and proves that nanomedicine can easily become a new medicinal product in personalized medicine.